Literature DB >> 2496166

Cyclosporin A-mediated inhibition of mitogen-induced gene transcription is specific for the mitogenic stimulus and cell type.

K C Gunter1, S G Irving, P F Zipfel, U Siebenlist, K Kelly.   

Abstract

We have examined the effect of cyclosporin A (CSA) on the mitogen-induced expression of 11 genes previously cloned from mitogen-activated T lymphocytes. Levels of induced gene expression in the human T cell line Jurkat were determined by mRNA blotting and nuclear run-on assay, after stimulation with one or combinations of the mitogens PMA, PHA, and the ionophore A23187. In the presence of CSA, gene expression induced with PMA alone was not inhibited, whereas PHA-induced increases in gene expression were inhibited by CSA. For one group of genes, including IL-2 and two novel genes with sequences suggestive of lymphokines, A23187 plus PMA-induced gene expression was inhibited by CSA. In contrast, another group of induced genes was unaffected by CSA after A23187 and PMA induction. This finding implies that A23187 and PMA stimulate gene induction by more than one mechanism, and that not all activation signals mediated through calcium fluxes are sensitive to CSA. In addition, 8 of the 11 genes were expressed in the fibroblast cell line Mrc 5 after stimulation with PMA, A23187, or serum; CSA had no effect on genes induced with these agents in Mrc 5 cells in both mRNA blotting and run-on experiments, although 5 of these genes were markedly inhibited by CSA in Jurkat after PMA/PHA induction. These data indicate that separate pathways for induction of identical genes exist, and that the inciting stimulus and cell type are determining factors in the ability of CSA to inhibit gene expression.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2496166

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  International consensus recommendations on cyclosporin use in rheumatoid arthritis.

Authors:  P Tugwell
Journal:  Drugs       Date:  1995       Impact factor: 9.546

2.  Inducible nuclear factor binding to the kappa B elements of the human immunodeficiency virus enhancer in T cells can be blocked by cyclosporin A in a signal-dependent manner.

Authors:  A Schmidt; L Hennighausen; U Siebenlist
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

3.  Interleukin-2-dependent phosphorylation of the retinoblastoma-susceptibility-gene product p110-115RB in human T-cells.

Authors:  G A Evans; L M Wahl; W L Farrar
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

4.  The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1.

Authors:  S S Banerji; J N Parsons; M J Tocci
Journal:  Mol Cell Biol       Date:  1991-08       Impact factor: 4.272

5.  Inhibitory effect of cyclosporin A on T lymphocyte DNA synthesis.

Authors:  M Li; H Zhang; J Yang; J F Shao; H Y Jiang
Journal:  J Tongji Med Univ       Date:  1992

6.  Induction of the early growth response (Egr) family of transcription factors during thymic selection.

Authors:  H Shao; D H Kono; L Y Chen; E M Rubin; J Kaye
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

7.  MIP1 alpha nuclear protein (MNP), a novel transcription factor expressed in hematopoietic cells that is crucial for transcription of the human MIP-1 alpha gene.

Authors:  L M Ritter; M Bryans; O Abdo; V Sharma; N M Wilkie
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

8.  Cyclosporin A does not affect the absolute rate of cortical bone resorption at the organ level in the growing rat.

Authors:  L Klein; M S Lemel; M S Wolfe; J Shaffer
Journal:  Calcif Tissue Int       Date:  1994-10       Impact factor: 4.333

9.  Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B.

Authors:  B Frantz; E C Nordby; G Bren; N Steffan; C V Paya; R L Kincaid; M J Tocci; S J O'Keefe; E A O'Neill
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.